Consensus Enlivex

Stocks

ENLV

IL0011319527

Market Closed - Nasdaq 16:00:00 2026-08-28 EDT			5-day change	1st Jan Change
1.350 ^USD	-8.47%		-10.00%	-87.20%

07-28	Enlivex Ltd. announced that it expects to receive $400 million in funding	CI
07-13	Enlivex Receives FDA Regenerative Medicine Advanced Therapy Designation for Allocetra in Age-Related Knee Osteoarthritis	CI

Evolution of the Average Target: Enlivex

Evolution of the Target Price: Enlivex

Changes in Analyst Recommendations: Enlivex

7ab0069e.R9z5yVkMG9Ww3ySq6l9tDPgDy0ahnCkFJ-H3KRxHmq0.KY2dhAZff4GAkxzNtRZAIZdWsjXVyH5uEYKFXl8Ow_8ziImIF1pK7f-MSw~9f41b7837640e80f9cda71696177243a

Analysts' recommendations: Enlivex

24-06-11	HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating	MT
24-04-12	HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating	MT
23-09-25	HC Wainwright Cuts Enlivex Therapeutics Price Target to $12 From $15, Maintains Buy Rating	MT
22-05-02	HC Wainwright Adjusts Enlivex Therapeutics' Price Target to $15 from $33, Keeps Buy Rating	MT

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

1.350USD

Average target price

80.00USD

Spread / Average Target

+5,825.93%

High Price Target

80.00USD

Spread / Highest target

+5,825.93%

Low Price Target

80.00USD

Spread / Lowest Target

+5,825.93%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
ENLV Stock
Consensus Enlivex

As early as today, start finding the best investment opportunities!